Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2261 to 2270 of 2636 total matches.
Dexmethylphenidate (Focalin) For ADHD
The Medical Letter on Drugs and Therapeutics • May 13, 2002 (Issue 1130)
Rochelle,
NY 10801-7537. Subscription fees: 1 year, $55.00; 2 years, $94.00; 3 years, $132.00 ($27.50—U.S ...
Dexmethylphenidate (Focalin - Novartis), a new formulation of methylphenidate (Ritalin, and others) is now available for treatment of attention deficit/hyperactivity disorder (ADHD). Dexmethylphenidate is the d-threo-enantiomer of racemic methylphenidate. "Now the right half may be all your patients need," said a recent ad. Focalin is the third new methylphenidate formulation marketed in the last two years.
Beta Interferons for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Oct 14, 2002 (Issue 1141)
BETA INTERFERONS FOR MS
Drug Dosage Cost
1
Interferon β-1a − Avonex (Biogen) 30 µg weekly IM $12,808 ...
Three beta interferons are widely used in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).
Rasburicase (Elitek) for Hyperuricemia
The Medical Letter on Drugs and Therapeutics • Nov 11, 2002 (Issue 1143)
*
Allopurinol
generic 150-300 mg PO $ 1.82
Zyloprim (Prometheus) 2.20
Aloprim (Nabi) 200 mg/m
2
IV 1290.00 ...
Rasburicase (Elitek - Sanofi-Synthelabo), a recombinant form of urate oxidase derived from the fungus Aspergillus flavus, has been approved by the FDA for intravenous (IV) management of hyperuricemia associated with tumor lysis syndrome in pediatric patients.
Drug-eluting Stents
The Medical Letter on Drugs and Therapeutics • Mar 17, 2003 (Issue 1152)
(SIRIUS) randomized 1,101 patients with previously untreated coronary lesions, including some with longer ...
Most angioplasty procedures for coronary artery disease now include placement of stents, which have improved both short- and long-term success rates. The main limitation is restenosis, which occurs in about 25% of patients. Drug-eluting stents intended to reduce the incidence of restenosis have been approved for use in Europe, but not yet in the US.
Cinacalcet (Sensipar)
The Medical Letter on Drugs and Therapeutics • Sep 20, 2004 (Issue 1192)
concentrations.
1
CLINICAL STUDIES — Three placebo-controlled clinical trials in patients ...
Cinacalcet hydrochloride (Sensipar - Amgen) has been approved by the FDA for treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis and treatment of hypercalcemia in patients with parathyroid carcinoma.
Clarification: Hand Hygiene and CDAD
The Medical Letter on Drugs and Therapeutics • Jan 29, 2007 (Issue 1253)
will not eradicate C.
difficile spores.”
1
One reader pointed out that alcoholbased products do eradicate some C ...
In the recent Medical Letter article on the treatment of Clostridium difficile–associated disease (CDAD) we wrote: “Healthcare workers caring for patients with C. difficile infection should follow contact isolation precautions, especially use of gloves and hand washing with soap and water after glove removal. Alcohol-based products such as hand sanitizers will not eradicate C. difficile spores.”1 One reader pointed out that alcoholbased products do eradicate some C. difficile spores and have been invaluable against other pathogens.In an unpublished study available as an abstract, both...
In Brief: Toxicity of Gadolinium-Based Contrast Agents
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007 (Issue 1262)
, that gadolinium-based
agents may also be nephrotoxic.
1
One patient who developed acute renal failure after use ...
Gadolinium-based contrast agents, which are used mainly for magnetic resonance imaging and angiography, were first introduced partly because of the discovery in the 1990’s that iodine-based contrast agents could cause nephrotoxicity and acute renal failure. Some recent reports have suggested, however, that gadolinium-based agents may also be nephrotoxic.1 One patient who developed acute renal failure after use of gadolinium-based contrast had a renal biopsy that showed acute tubular injury.2Moreover, after exposure to gadolinium-based contrast, some patients with severe renal insufficiency,...
Addendum: Warfarin-Acetaminophen Interaction
The Medical Letter on Drugs and Therapeutics • Jun 16, 2008 (Issue 1288)
Interactions”
1
did not
include acetaminophen. Perhaps it should have.
Acetaminophen can increase ...
A reader expressed disappointment that our recent listing of “Some Warfarin Drug Interactions”1 did not include acetaminophen. Perhaps it should have. Acetaminophen can increase the anticoagulant effect of warfarin, particularly with continued use, but it does so inconsistently. The mechanism of this interaction has not been established, but may be related to an acetaminophen metabolite inhibiting vitamin K-epoxide reductase, the target for warfarin’s anticoagulant effect.2Patient susceptibility varies, possibly on a genetic basis; occasional use of acetaminophen generally has little or...
Varenicline (Chantix) Warnings: Risk Versus Benefit
The Medical Letter on Drugs and Therapeutics • Jul 14, 2008 (Issue 1290)
,
1
but the
FDA has added a warning to the package insert about
neuropsychiatric symptoms ...
The nicotine receptor partial agonist varenicline (Chantix - Pfizer) appears to be the most effective drug available to treat tobacco dependence, but the FDA has added a warning to the package insert about neuropsychiatric symptoms and exacerbations of preexisting psychiatric illness associated with its use. Agitation, hostility, depressed mood, suicidal ideation and suicidal behavior have been reported as postmarketing adverse events in patients who took varenicline and stopped smoking and in those who took the drug and continued to smoke.
ECGs Before Stimulants in Children
The Medical Letter on Drugs and Therapeutics • Jul 28, 2008 (Issue 1291)
being
evaluated for stimulant drug therapy for attention
deficit hyperactivity disorder (ADHD).
1 ...
The American Heart Association (AHA) recently published a statement saying that it would be reasonable to obtain an electrocardiogram (ECG) in children being evaluated for stimulant drug therapy for attention deficit hyperactivity disorder (ADHD). A subsequent news release in conjunction with the American Academy of Pediatrics provided a clarification, saying that it would be reasonable to consider obtaining an ECG in such children.
